FDA Clearance Tracker · P040024-S146
Restylane® Lyft with Lidocaine
Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Dec 23, 2025
Approved
Time to decision
21 days
Received Dec 2, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the postapproval study (PAS) protocol submitted to comply with the conditions of approval outlined in the approval order for P040024/S142.
Source documents
Other decisions for Q-Med AB
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Restylane® ContourPMA supplement
P140029-S054 · Decided Mar 20, 2026 · 239 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.